457 related articles for article (PubMed ID: 26031842)
1. Tumor vascular targeted liposomal-bortezomib minimizes side effects and increases therapeutic activity in human neuroblastoma.
Zuccari G; Milelli A; Pastorino F; Loi M; Petretto A; Parise A; Marchetti C; Minarini A; Cilli M; Emionite L; Di Paolo D; Brignole C; Piaggio F; Perri P; Tumiatti V; Pistoia V; Pagnan G; Ponzoni M
J Control Release; 2015 Aug; 211():44-52. PubMed ID: 26031842
[TBL] [Abstract][Full Text] [Related]
2. Enhanced anti-tumor and anti-angiogenic efficacy of a novel liposomal fenretinide on human neuroblastoma.
Di Paolo D; Pastorino F; Zuccari G; Caffa I; Loi M; Marimpietri D; Brignole C; Perri P; Cilli M; Nico B; Ribatti D; Pistoia V; Ponzoni M; Pagnan G
J Control Release; 2013 Sep; 170(3):445-51. PubMed ID: 23792118
[TBL] [Abstract][Full Text] [Related]
3. The Effect of Phase Transition Temperature on Therapeutic Efficacy of Liposomal Bortezomib.
Korani M; Nikoofal-Sahlabadi S; Nikpoor AR; Ghaffari S; Attar H; Mashreghi M; Jaafari MR
Anticancer Agents Med Chem; 2020; 20(6):700-708. PubMed ID: 31893998
[TBL] [Abstract][Full Text] [Related]
4. sTRAIL coupled to liposomes improves its pharmacokinetic profile and overcomes neuroblastoma tumour resistance in combination with Bortezomib.
Loi M; Becherini P; Emionite L; Giacomini A; Cossu I; Destefanis E; Brignole C; Di Paolo D; Piaggio F; Perri P; Cilli M; Pastorino F; Ponzoni M
J Control Release; 2014 Oct; 192():157-66. PubMed ID: 25041999
[TBL] [Abstract][Full Text] [Related]
5. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
6. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy.
Pastorino F; Brignole C; Di Paolo D; Nico B; Pezzolo A; Marimpietri D; Pagnan G; Piccardi F; Cilli M; Longhi R; Ribatti D; Corti A; Allen TM; Ponzoni M
Cancer Res; 2006 Oct; 66(20):10073-82. PubMed ID: 17047071
[TBL] [Abstract][Full Text] [Related]
7. Combined targeting of perivascular and endothelial tumor cells enhances anti-tumor efficacy of liposomal chemotherapy in neuroblastoma.
Loi M; Marchiò S; Becherini P; Di Paolo D; Soster M; Curnis F; Brignole C; Pagnan G; Perri P; Caffa I; Longhi R; Nico B; Bussolino F; Gambini C; Ribatti D; Cilli M; Arap W; Pasqualini R; Allen TM; Corti A; Ponzoni M; Pastorino F
J Control Release; 2010 Jul; 145(1):66-73. PubMed ID: 20346382
[TBL] [Abstract][Full Text] [Related]
8. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
9. Hyaluronic acid shell and disulfide-crosslinked core micelles for in vivo targeted delivery of bortezomib for the treatment of multiple myeloma.
Gu Z; Wang X; Cheng R; Cheng L; Zhong Z
Acta Biomater; 2018 Oct; 80():288-295. PubMed ID: 30240956
[TBL] [Abstract][Full Text] [Related]
10. Liposome-mediated therapy of neuroblastoma.
Di Paolo D; Loi M; Pastorino F; Brignole C; Marimpietri D; Becherini P; Caffa I; Zorzoli A; Longhi R; Gagliani C; Tacchetti C; Corti A; Allen TM; Ponzoni M; Pagnan G
Methods Enzymol; 2009; 465():225-49. PubMed ID: 19913170
[TBL] [Abstract][Full Text] [Related]
11. Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.
Parise A; Milelli A; Tumiatti V; Minarini A; Neviani P; Zuccari G
Drug Deliv; 2015; 22(5):590-7. PubMed ID: 24286206
[TBL] [Abstract][Full Text] [Related]
12. Bortezomib-loaded lipidic-nano drug delivery systems; formulation, therapeutic efficacy, and pharmacokinetics.
Mahmoudian M; Valizadeh H; Löbenberg R; Zakeri-Milani P
J Microencapsul; 2021 May; 38(3):192-202. PubMed ID: 33530812
[TBL] [Abstract][Full Text] [Related]
13. Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs.
Brignole C; Pastorino F; Marimpietri D; Pagnan G; Pistorio A; Allen TM; Pistoia V; Ponzoni M
J Natl Cancer Inst; 2004 Aug; 96(15):1171-80. PubMed ID: 15292389
[TBL] [Abstract][Full Text] [Related]
14. Glycine-Poly-L-Lactic Acid Copolymeric Nanoparticles for the Efficient Delivery of Bortezomib.
Rajoria S; Rani S; Chaudhari D; Jain S; Gupta U
Pharm Res; 2019 Sep; 36(11):160. PubMed ID: 31520196
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of doxorubicin using stealth liposomes modified with transferrin.
Li X; Ding L; Xu Y; Wang Y; Ping Q
Int J Pharm; 2009 May; 373(1-2):116-23. PubMed ID: 19429296
[TBL] [Abstract][Full Text] [Related]
16. Doxorubicin-loaded Fab' fragments of anti-disialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice.
Pastorino F; Brignole C; Marimpietri D; Sapra P; Moase EH; Allen TM; Ponzoni M
Cancer Res; 2003 Jan; 63(1):86-92. PubMed ID: 12517782
[TBL] [Abstract][Full Text] [Related]
17. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin.
Pastorino F; Di Paolo D; Piccardi F; Nico B; Ribatti D; Daga A; Baio G; Neumaier CE; Brignole C; Loi M; Marimpietri D; Pagnan G; Cilli M; Lepekhin EA; Garde SV; Longhi R; Corti A; Allen TM; Wu JJ; Ponzoni M
Clin Cancer Res; 2008 Nov; 14(22):7320-9. PubMed ID: 19010847
[TBL] [Abstract][Full Text] [Related]
18. Neuroblastoma-targeted nanocarriers improve drug delivery and penetration, delay tumor growth and abrogate metastatic diffusion.
Cossu I; Bottoni G; Loi M; Emionite L; Bartolini A; Di Paolo D; Brignole C; Piaggio F; Perri P; Sacchi A; Curnis F; Gagliani MC; Bruno S; Marini C; Gori A; Longhi R; Murgia D; Sementa AR; Cilli M; Tacchetti C; Corti A; Sambuceti G; Marchiò S; Ponzoni M; Pastorino F
Biomaterials; 2015 Nov; 68():89-99. PubMed ID: 26276694
[TBL] [Abstract][Full Text] [Related]
19. Bortezomib inhibits angiogenesis and reduces tumor burden in a murine model of neuroblastoma.
Hamner JB; Dickson PV; Sims TL; Zhou J; Spence Y; Ng CY; Davidoff AM
Surgery; 2007 Aug; 142(2):185-91. PubMed ID: 17689684
[TBL] [Abstract][Full Text] [Related]
20. HO-1 up-regulation: a key point in high-risk neuroblastoma resistance to bortezomib.
Furfaro AL; Piras S; Passalacqua M; Domenicotti C; Parodi A; Fenoglio D; Pronzato MA; Marinari UM; Moretta L; Traverso N; Nitti M
Biochim Biophys Acta; 2014 Apr; 1842(4):613-22. PubMed ID: 24380881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
